Key statistics
On Friday, NRX Pharmaceuticals Inc (NRXP:NAQ) closed at 1.80, 13.92% above the 52 week low of 1.58 set on Apr 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.73 |
|---|---|
| High | 1.82 |
| Low | 1.73 |
| Bid | 1.80 |
| Offer | 1.82 |
| Previous close | 1.73 |
| Average volume | 505.94k |
|---|---|
| Shares outstanding | 28.10m |
| Free float | 25.35m |
| P/E (TTM) | -- |
| Market cap | 50.58m USD |
| EPS (TTM) | -2.32 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
- NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions
- NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
- NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
- NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
- NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call
- NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025
More ▼
